{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:17:37Z","timestamp":1787804257521,"version":"build-2784847793"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":155,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Empagliflozin reduces cardiovascular death (CVD) or hospitalization for heart failure (HHF), slows estimated glomerular filtration rate (eGFR) decline and improves quality of life (QoL) in heart failure with reduced ejection fraction (HFrEF). Whether the effect of empagliflozin is consistent according to atrial fibrillation (AF) status is worth exploring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The impact of AF versus sinus rhythm (SR) on outcomes as well as on eGFR decline and QoL were studied post-hoc in EMPEROR-Reduced. Of patients with available rhythm analyses and after exclusion of patients with missing or paced rhythms, 2785 were included (AF, n\u2009=\u2009928, SR, n\u2009=\u20091857). Differences were not significant for the primary endpoint (p\u2009=\u20090.66), first (p\u2009=\u20090.19) and recurrent HHF (p\u2009=\u20090.45). On placebo, alcohol consumption (interaction p\u2009=\u20090.32), body mass index (interaction p\u2009=\u20090.93), diabetes (interaction p\u2009=\u20090.52), hypertension (interaction p\u2009=\u20090.24) were not different between AF and SR. Low ejection fraction and high Kidney Disease: Improving Global Outcomes (KDIGO) class had higher event rates but without interaction between SR and AF, respectively. After a median follow-up of 20\u2009months, empagliflozin reduced CVD or HHF compared to placebo in AF and SR (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.63\u20131.08; and HR 0.69, 95% CI 0.56\u20130.84; interaction p\u2009=\u20090.29). The same applied to time to first HHF (interaction p\u2009=\u20090.20), while there was a borderline but insignificant interaction for first and recurrent HHF (p\u2009=\u20090.10). The effect on annual eGFR decline and QoL scores was not different. Incident AF was numerically lower but formally not significantly different (HR 0.66, 95% CI 0.40\u20131.09, p\u2009=\u20090.11, empagliflozin vs. placebo).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFrEF, AF did not significantly modify outcomes after adjustment and did not associate with eGFR slopes. Empagliflozin reduced outcomes, eGFR decline and improved QoL regardless of AF or SR and probably reduced incident AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.70021","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T13:51:02Z","timestamp":1758030662000},"page":"2218-2228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heart Failure Outcomes and Empagliflozin Effects in Patients with Heart Failure and Reduced Ejection Fraction in Sinus Rhythm or Atrial Fibrillation: Data from EMPEROR-Reduced"],"prefix":"10.1093","volume":"27","author":[{"given":"Michael","family":"B\u00f6hm","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi School of Medicine , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Abdin","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigation Clinique-Plurith\u00e9matique Inserm CIC-P 1433; Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]},{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International , Ingelheim ,","place":["Germany"]},{"name":"First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pernille","family":"Ofstad","sequence":"additional","affiliation":[{"name":"Oslo Diabetes Research Center and Medical Department Boehringer Ingelheim Norway KS , Asker ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schueler","sequence":"additional","affiliation":[{"name":"mainanalytics GmbH , Sulzbach\/Taunus ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigation Clinique-Plurith\u00e9matique Inserm CIC-P 1433; Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center , Dallas, TX ,","place":["USA"]},{"name":"Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2026021721491559500_ejhf70021-bib-0001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: The Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"2026021721491559500_ejhf70021-bib-0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/eurjpc\/zwad270","article-title":"Changes in alcohol consumption habits and risk of atrial fibrillation: A nationwide population-based study","volume":"31","author":"Lee","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0003","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1001\/archinte.166.21.2322","article-title":"Risk of new-onset atrial fibrillation in relation to body mass index","volume":"166","author":"Dublin","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026021721491559500_ejhf70021-bib-0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","article-title":"Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: A Swedish cohort study","volume":"19","author":"Seyed Ahmadi","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026021721491559500_ejhf70021-bib-0005","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0006","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)","volume":"159","author":"Soliman","year":"2010","journal-title":"Am Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0007","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/eurheartj\/ehab834","article-title":"Atrial disease and heart failure: The common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology","volume":"43","author":"Coats","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721491559500_ejhf70021-bib-0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721491559500_ejhf70021-bib-0010","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure","volume":"69","author":"Kotecha","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF","volume":"24","author":"Butt","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721491559500_ejhf70021-bib-0012","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurheartj\/ehi166","article-title":"Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0013","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","article-title":"Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction","volume":"70","author":"Mogensen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0014","first-page":"VI102","article-title":"The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Carson","year":"1993","journal-title":"Circulation"},{"key":"2026021721491559500_ejhf70021-bib-0015","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/euhj.1999.2107","article-title":"Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure","volume":"21","author":"Crijns","year":"2000","journal-title":"Eur Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","volume":"80","author":"B\u00f6hm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0017","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","article-title":"Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"5","author":"Sartipy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026021721491559500_ejhf70021-bib-0019","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1093\/eurheartj\/ehy626","article-title":"Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14\u2009964 patients in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"39","author":"Zafrir","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021721491559500_ejhf70021-bib-0020","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721491559500_ejhf70021-bib-0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0022","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: From physician's prescriptions to patient's dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721491559500_ejhf70021-bib-0023","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0024","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: A nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026021721491559500_ejhf70021-bib-0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.amjcard.2025.03.002","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on atrial fibrillation burden in diabetic patients","volume":"246","author":"Kidess","year":"2025","journal-title":"Am J Cardiol"},{"key":"2026021721491559500_ejhf70021-bib-0026","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","article-title":"Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes","volume":"9","author":"Abu-Qaoud","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"2026021721491559500_ejhf70021-bib-0027","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jce.16621","article-title":"The impact of SGLT2 inhibitors on atrial fibrillation recurrence and long-term clinical outcomes in HFrEF patients undergoing cryoballoon ablation: A new frontier beyond diabetes and heart failure","volume":"36","author":"Cetin","year":"2025","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026021721491559500_ejhf70021-bib-0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: Novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"2026021721491559500_ejhf70021-bib-0029","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026021721491559500_ejhf70021-bib-0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.17305\/bb.2024.11361","article-title":"Dapagliflozin and sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model","volume":"25","author":"Lee","year":"2025","journal-title":"Biomol Biomed"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2218\/66833799\/eurjhf_27_11_2218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2218\/66833799\/eurjhf_27_11_2218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:49:24Z","timestamp":1771382964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2218\/8470132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70021","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"2025-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}